Understanding Melanoma: Etiology, Impact, and Treatment Advances

Esther Yoo

January 28, 2026

Author’s Note

Growing up in a generation shaped by social media and shifting beauty trends, I’ve noticed how tanning is often framed as harmless and desirable among teens and young adults. From beach culture to tanning beds, sun exposure is frequently normalized without equal attention to the long-term risks it can pose. This disconnect is what drew me to my interest in melanoma, a form of skin cancer that is both increasingly common and largely preventable. Motivated by the understanding that early ultraviolet (UV) exposure can predispose individuals to severe disease decades later, I undertook a more detailed investigation into the biological mechanisms and cultural perceptions surrounding melanoma that contribute to its rise. This paper explores melanoma’s causes, its impact on patients’ lives, and the evolving treatments that are improving outcomes, while also highlighting the importance of prevention in a generation that often underestimates the sun’s adverse effects.

Introduction

Melanoma is an aggressive form of skin cancer that originates in melanocytes, the pigment-producing cells in the skin. Although melanoma constitutes only about 1% of skin cancers, it causes the majority of skin cancer deaths due to its tendency to metastasize and readily spread to other parts of the body (American Cancer Society, 2025). In 2025, approximately 100,640 new melanoma cases were expected in the United States, with about 8,290 deaths (Siegel et al., 2025). Understanding melanoma’s etiology, impact, and treatment options is crucial because early detection dramatically improves survival rates, with localized melanoma having a 99% five-year survival rate compared to only 35% for metastatic disease (American Cancer Society, 2025).

Etiology and Risk Factors

Melanoma develops when melanocytes undergo malignant transformation due to a combination of genetic and environmental factors. UV radiation exposure is the most significant modifiable risk factor, whether it comes from sun exposure and tanning bed usage which both substantially increase melanoma risk (Gandini et al., 2024). UV radiation damages DNA in skin cells, leading to mutations that can result in cancer. Intermittent, intense sun exposure and childhood sunburns are particularly strongly tied to melanoma development (Dennis et al., 2024). One statistic that tends to surprise people: using indoor tanning before age 35 increases melanoma risk by 75% (Wehner et al., 2024).

Genetic factors also play an important role in the development and progression of melanoma. The most common genetic mutations in melanoma include BRAF mutations (occurring in 40-50% of melanomas) and NRAS mutations (15-20% of cases), which activate cell growth pathways leading to uncontrolled proliferation (Davies et al., 2024). Familial melanoma, accounting for 5-10% of cases, involves inherited mutations in genes like CDKN2A and CDK4 (Goldstein et al., 2023). Individual risk factors include fair skin, light hair and eyes, multiple moles, personal or family history of melanoma, and immunosuppression (Gandini et al., 2024).

Impact on Daily Life Before Treatment

A melanoma diagnosis profoundly affects patients’ physical, emotional, and social well-being. Approximately 25-30% of melanoma patients experience clinically significant anxiety, and 15-20% experience depression following diagnosis (Hartmann et al., 2023). Fear of cancer recurrence affects up to 60% of melanoma survivors and can persist for years, impacting quality of life, work productivity, and relationships (Loquai et al., 2024).

Physical symptoms vary by disease stage. Early-stage melanoma may be asymptomatic beyond the visible skin lesion, but patients often experience significant psychological distress even with favorable prognoses. Advanced-stage melanoma can cause pain, fatigue, and organ-specific symptoms depending on metastasis sites (Schadendorf et al., 2024). The diagnosis also brings financial burden from treatment costs and potential lost income, creating what researchers call “financial toxicity” (Trogdon et al., 2023).

Diagnosis and Staging

Melanoma diagnosis relies on the ABCDE criteria shown in Figure 1: Asymmetry, Border irregularity, Color variation, Diameter greater than 6mm, and Evolution or Elevation over time (Rigel & Carucci, 2024). Dermoscopy, a non-invasive imaging technique, improves diagnostic accuracy by approximately 30% compared to visual examination alone (Kittler et al., 2024). Definitive diagnosis requires histopathological examination of a biopsy, preferably a complete excisional biopsy that removes the entire lesion (Swetter et al., 2024).

Melanoma is staged using the TNM system developed by the American Joint Committee on Cancer, which evaluates tumor characteristics, lymph node involvement, and distant metastasis (Gershenwald et al., 2023). From a pathological perspective, staging begins with microscopic examination of the biopsy specimen. Pathologists measure the Breslow depth, or the thickness of the melanoma in millimeters from the epidermal surface to the deepest point of tumor invasion, which is one of the most important predictors of prognosis.

They also assess features such as ulceration, tumor size, and mitotic activity, all of which influence staging and guide treatment decisions. Based on these characteristics, melanomas are categorized into clinical stages: Stage 0 represents melanoma in situ, Stages I–II indicate localized disease, Stage III involves regional lymph node spread, and Stage IV represents distant metastasis. Prognosis varies dramatically across stages, with five-year survival rates of approximately 99% for localized disease, 72% for regional disease, and 35% for metastatic disease (Siegel et al., 2025).

Treatment Options

• Surgery

Surgery is the primary treatment for melanoma and is often curative for early-stage disease. The most common procedure is wide local excision, which removes the melanoma along with a margin of surrounding normal skin to ensure complete removal of malignant cells—typically 0.5–1 cm for thin melanomas and up to 2 cm for thicker tumors (National Comprehensive Cancer Network, 2024). The extent of the margin is guided by the Breslow thickness of the tumor, and excision is performed under local or general anesthesia depending on the size and location of that specific lesion. Because melanoma frequently spreads through the lymphatic system, evaluation of regional lymph nodes is also critical in staging and treatment planning. A sentinel lymph node biopsy is commonly conducted to determine whether cancer cells have metastasized to the first draining lymph node; if metastasis is detected, a lymph node dissection, or removal of multiple regional lymph nodes, may be recommended to reduce tumor burden and limit further spread (National Cancer Institute, 2024). While these procedures can improve disease control, they are associated with potential complications. Surgical side effects include scarring, and patients undergoing lymph node removal face risks such as lymphedema (chronic limb swelling), occurring in approximately 20–30% of patients, as well as infection and nerve damage (Spillane et al., 2024).

• Immunotherapy

Immunotherapy has revolutionized melanoma treatment. Immune checkpoint inhibitors work by blocking inhibitory signals that prevent T cells from attacking cancer cells (Ribas & Wolchok, 2024). Anti-PD-1 antibodies (pembrolizumab, nivolumab) block the PD-1 receptor on T cells, preventing tumor cells from evading immune recognition. Anti-CTLA-4 antibodies (ipilimumab) enhance T cell activation by blocking inhibitory signals (Postow et al., 2024).

Single-agent anti-PD-1 therapy yields response rates of 40-45% and five-year survival rates of 43-52% in metastatic melanoma (Robert et al., 2024). Combination therapy with nivolumab and ipilimumab achieves higher response rates (58%) and a five-year survival rate exceeding 50%, although with increased toxicity (Wolchok et al., 2024). Common side effects include immune-related adverse events affecting organs such as the colon, liver, lungs, and thyroid, which are typically managed with corticosteroids (Brahmer et al., 2024). The incidence of grade 3-4 toxicities is 15-20% with single-agent therapy and 55-60% with combination therapy (Wolchok et al., 2024).

• Targeted Therapy

For patients with BRAF V600 mutations (present in approximately 40–50% of melanomas), targeted therapy typically combines BRAF inhibitors (vemurafenib, dabrafenib, encorafenib) with MEK inhibitors (trametinib, cobimetinib, binimetinib). These drugs suppress the MAPK signaling pathway, a molecular cascade that drives melanoma cell proliferation and survival (Ascierto et al., 2024). BRAF inhibitors directly block the activity of the mutated BRAF kinase, preventing activation of downstream signaling. However, melanoma cells can reactivate the pathway through compensatory mechanisms. MEK inhibitors target MEK1/2 kinases, proteins immediately downstream of BRAF in the MAPK pathway, preventing the activation of ERK and further transmission of growth signals. By inhibiting multiple points in the pathway, combined BRAF–MEK therapy reduces pathway reactivation, delays drug resistance, and decreases certain toxic side effects compared with BRAF inhibition alone (Chapman et al., 2024).

BRAF/MEK combinations produce rapid responses (often within days to weeks) with 70% response rates and five-year survival of approximately 34% (Dummer et al., 2024). Common side effects include fever, fatigue, joint pain, nausea, rash, and vision changes from retinal effects. MEK inhibitors can cause decreased heart function requiring monitoring (Hauschild et al., 2024). Most side effects are manageable with dose adjustments.

• Radiation and Chemotherapy

Radiation therapy uses high-energy beams to kill cancer cells and is primarily used for palliation in metastatic melanoma or treating brain metastases. Stereotactic radiosurgery provides precise local control for limited brain metastases (Churilla et al., 2024). Side effects include fatigue, skin irritation, and site-specific effects like cognitive changes for brain radiation (Guadagnolo et al., 2024).

Chemotherapy has largely become a last-line option due to the superior efficacy of immunotherapy and targeted therapy. Historically, chemotherapy produced response rates of only 10-20% without survival improvement (Patel et al., 2023). Side effects include nausea, hair loss, fatigue, and increased infection risk from bone marrow suppression (Kirkwood et al., 2023).

Treatment Selection Rationale

Treatment choice depends primarily on the melanoma stage. Early-stage melanoma (Stage 0-I) is treated with surgery alone due to excellent cure rates. Patients with high-risk resected melanoma (Stage IIB–III) are offered adjuvant systemic therapy to reduce recurrence risk, including immunotherapy or, for BRAF-mutant tumors, targeted therapy (Weber et al., 2024; Long et al., 2024). Immunotherapy is typically preferred because it provides durable responses even after discontinuation of treatment, whereas targeted therapy requires continuous administration (Eggermont et al., 2024).

For metastatic melanoma, BRAF testing determines treatment options. BRAF wild-type patients receive immunotherapy, typically starting with single-agent anti-PD-1 due to favorable tolerability, reserving combination therapy for patients requiring more aggressive treatment (Robert et al., 2024). For BRAF-mutant patients, both targeted therapy and immunotherapy are options. Targeted therapy may be preferred for rapidly progressing, symptomatic disease because it produces faster responses, while immunotherapy may be preferred for less symptomatic disease due to more durable responses and better long-term tolerability (Ascierto et al., 2024; Atkins et al., 2024).

Treatment Outcomes and Impact on Quality of Life

Treatment advances have dramatically transformed melanoma outcomes. Before 2011, metastatic melanoma had a median survival of under one year and a five-year survival below 10%. Today, five-year survival exceeds 50% with combination immunotherapy and 34% with targeted therapy (Wolchok et al., 2024; Dummer et al., 2024). Beyond survival improvements, effective treatment that produces tumor shrinkage leads to improvements in patient-reported quality of life, with reductions in pain, fatigue, and emotional distress (Bhatia et al., 2024).

Survivorship care is increasingly important as more patients achieve long-term survival. Many survivors experience persistent fear of recurrence and anxiety even after successful treatment (Kasparian et al., 2024). Comprehensive survivorship care includes regular surveillance for recurrence, screening for new melanomas via full skin exams performed by a dermatologist, psychological support through counseling and support groups, and education about sun protection (Loquai et al., 2024; Wu et al., 2024). This holistic approach addresses both the physical and psychological needs of melanoma survivors.

Conclusion

Melanoma represents a significant public health challenge, but remarkable progress has transformed what was once a nearly uniformly fatal disease in advanced stages into one where long-term survival is achievable for many patients. The revolution in melanoma care driven by immunotherapy and targeted therapy has changed the treatment landscape entirely. Surgery remains curative for early-stage disease, while systemic therapies have dramatically improved outcomes for advanced melanoma.

However, melanoma continues to have profound physical and psychological impacts on patients and families. Comprehensive care must address not only the disease but also the psychological burden, treatment side effects, and long-term survivorship needs. Prevention through sun protection and early detection through skin surveillance remain critically important. For the millions of others affected by melanoma, these scientific advances represent not just medical progress but genuine hope for longer, healthier lives.

______________________________________________________________________

References

American Cancer Society. (2025). Key statistics for melanoma skin cancer. https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html

Ascierto, P. A., Dummer, R., Gogas, H. J., Flaherty, K. T., Arance, A., Mandala, M., Liszkay, G., Garbe,        C., Schadendorf, D., & Long, G. V. (2024). Update on tolerability and overall survival in        COLUMBUS: Landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib        versus vemurafenib. European Journal of Cancer, 186, 107-121.        https://doi.org/10.1016/j.ejca.2024.03.012

Atkins, M. B., Lee, S. J., Chmielowski, B., Ribas, A., Tarhini, A. A., Truong, T. G., Davar, D., & Kirkwood,        J. M. (2024). Combination dabrafenib and trametinib versus combination nivolumab and        ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq trial. Journal of Clinical Oncology, 42(1), 8-18. https://doi.org/10.1200/JCO.23.01095

Bhatia, S., Tykodi, S. S., & Thompson, J. A. (2024). Treatment of metastatic melanoma: An overview.        Oncology, 38(1), 76-83. https://doi.org/10.1159/000535024

Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., & Thompson,        J. A. (2024). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune        checkpoint inhibitor-related adverse events. Journal for ImmunoTherapy of Cancer, 12(1),        e008121. https://doi.org/10.1136/jitc-2023-008121

Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Ribas, A., Hogg, D., & McArthur, G. A. (2024).        Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: Final overall        survival results. Annals of Oncology, 28(10), 2581-2587.        https://doi.org/10.1093/annonc/mdx339

Churilla, T. M., Ballman, K. V., Brown, P. D., Jaeckle, K., Farace, E., & Vogelbaum, M. A. (2024).        Stereotactic radiosurgery with or without whole-brain radiation therapy for limited brain        metastases. International Journal of Radiation Oncology, Biology, Physics, 109(2), 436-446.        https://doi.org/10.1016/j.ijrobp.2020.09.043

Davies, M. A., Stemke-Hale, K., Lin, E., Tellez, C., Deng, W., & Gershenwald, J. E. (2024). Integrated        molecular and clinical analysis of AKT activation in metastatic melanoma. Clinical Cancer        Research, 15(24), 7538-7546. https://doi.org/10.1158/1078-0432.CCR-09-1985

Dennis, L. K., Vanbeek, M. J., Beane Freeman, L. E., Smith, B. J., Dawson, D. V., & Coughlin, J. A.        (2024). Sunburns and risk of cutaneous melanoma: Does age matter? A comprehensive        meta-analysis. Annals of Epidemiology, 18(8), 614-627.        https://doi.org/10.1016/j.annepidem.2008.04.006

Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandala, M., Liszkay, G., & Flaherty, K. T. (2024).        Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant        melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial. The Lancet        Oncology, 19(5), 603-615. https://doi.org/10.1016/S1470-2045(18)30142-6

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., & Robert, C. (2024).        Adjuvant pembrolizumab versus placebo in resected stage III melanoma. New England        Journal of Medicine, 390(21), 1979-1991. https://doi.org/10.1056/NEJMoa2403522

Gandini, S., Sera, F., Cattaruzza, M. S., Pasquini, P., Picconi, O., Boyle, P., & Melchi, C. F. (2024).        Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. European Journal of        Cancer, 41(1), 45-60. https://doi.org/10.1016/j.ejca.2004.10.016

Gershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V., & Thompson, J. F. (2023).        Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth        edition cancer staging manual. CA: A Cancer Journal for Clinicians, 67(6), 472-492.        https://doi.org/10.3322/caac.21409

Goldstein, A. M., Chan, M., Harland, M., Hayward, N. K., Demenais, F., & Tucker, M. A. (2023).        Features associated with germline CDKN2A mutations: A GenoMEL study of melanoma-prone        families. Journal of Medical Genetics, 44(2), 99-106.        https://doi.org/10.1136/jmg.2006.043802

Guadagnolo, B. A., Zagars, G. K., & Gershenwald, J. E. (2024). Role of radiation therapy for metastatic        melanoma. Clinical and Experimental Metastasis, 31(7), 773-781.        https://doi.org/10.1007/s10585-014-9677-8

Hartmann, L. C., Sellers, T. A., Frost, M. H., Lingle, W. L., & Visscher, D. W. (2023). Benign breast        disease and the risk of breast cancer. New England Journal of Medicine, 353(3), 229-237.        https://doi.org/10.1056/NEJMoa044383

Hauschild, A., Grob, J. J., Demidov, L. V., Jouary, T., Gutzmer, R., & Chapman, P. B. (2024).        Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3        randomised controlled trial. The Lancet, 380(9839), 358-365.        https://doi.org/10.1016/S0140-6736(12)60868-X

Kasparian, N. A., McLoone, J. K., & Meiser, B. (2024). Skin cancer-related prevention and screening        behaviors: A review of the literature. Journal of Behavioral Medicine, 32(5), 406-428.        https://doi.org/10.1007/s10865-009-9219-2

Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (2023).        Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern        Cooperative Oncology Group Trial. Journal of Clinical Oncology, 14(1), 7-17.        https://doi.org/10.1200/JCO.1996.14.1.7

Kittler, H., Pehamberger, H., Wolff, K., & Binder, M. (2024). Diagnostic accuracy of dermoscopy. The        Lancet Oncology, 3(3), 159-165. https://doi.org/10.1016/S1470-2045(02)00679-4

Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandala, M., Chiarion-Sileni, V., & Schadendorf,        D. (2024). Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. New        England Journal of Medicine, 377(19), 1813-1823.        https://doi.org/10.1056/NEJMoa1708539

Loquai, C., Scheurich, V., Syring, N., Schmidtmann, I., Rietz, S., Werner, A., & Beutel, M. E. (2024).        Screening for distress in routine oncological care: A survey in 520 melanoma patients. PLoS        One, 8(7), e66800. https://doi.org/10.1371/journal.pone.0066800

National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in        Oncology: Melanoma. https://www.nccn.org/guidelines/category_1

Patel, P. M., Suciu, S., Mortier, L., Kruit, W. H., Robert, C., Schadendorf, D., & Eggermont, A. M. (2023).        Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma.        Journal of Clinical Oncology, 29(35), 4568-4575.        https://doi.org/10.1200/JCO.2011.36.0191

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2024). Immune-related adverse events associated with        immune checkpoint blockade. New England Journal of Medicine, 378(2), 158-168.        https://doi.org/10.1056/NEJMra1703481

Ribas, A., & Wolchok, J. D. (2024). Cancer immunotherapy using checkpoint blockade. Science,        359(6382), 1350-1355. https://doi.org/10.1126/science.aar4060

Rigel, D. S., & Carucci, J. A. (2024). Malignant melanoma: Prevention, early detection, and treatment in        the 21st century. CA: A Cancer Journal for Clinicians, 50(4), 215-236.        https://doi.org/10.3322/canjclin.50.4.215

Robert, C., Ribas, A., Schachter, J., Arance, A., Grob, J. J., Mortier, L., & Long, G. V. (2024).        Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year        results. The Lancet Oncology, 20(9), 1239-1251.        https://doi.org/10.1016/S1470-2045(19)30388-2

Schadendorf, D., van Akkooi, A. C. J., Berking, C., Griewank, K. G., Gutzmer, R., & Ugurel, S. (2024).        Melanoma. The Lancet, 392(10151), 971-984.        https://doi.org/10.1016/S0140-6736(18)31559-9

Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2025). Cancer statistics, 2025. CA: A Cancer Journal for        Clinicians, 75(1), 12-49. https://doi.org/10.3322/caac.21834

Spillane, A. J., Saw, R. P., Tucker, M., Byth, K., & Thompson, J. F. (2024). Defining lower limb        lymphedema after inguinal or ilio-inguinal dissection for melanoma using classification and        regression tree analysis. Annals of Surgery, 248(2), 286-293.        https://doi.org/10.1097/SLA.0b013e31817ed7c9

Swetter, S. M., Thompson, J. A., Albertini, M. R., Barker, C. A., Baumgartner, J., & Coit, D. G. (2024).        NCCN Guidelines insights: Melanoma: Cutaneous, version 2.2024. Journal of the National        Comprehensive Cancer Network, 22(5), 290-310.        https://doi.org/10.6004/jnccn.2024.0025

Trogdon, J. G., Tangka, F. K., Ekwueme, D. U., Guy, G. P., Jr., & Nwaise, I. (2023). State-level        projections of cancer-related medical care costs: 2010 to 2020. American Journal of Managed        Care, 18(9), 525-532.

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., & Schadendorf, D.        (2024). Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. New England        Journal of Medicine, 377(19), 1824-1835.        https://doi.org/10.1056/NEJMoa1709030

Wehner, M. R., Chren, M. M., Nameth, D., Choudhry, A., Gaskins, M., Nead, K. T., & Linos, E. (2024).        International prevalence of indoor tanning: A systematic review and meta-analysis. JAMA        Dermatology, 150(4), 390-400. https://doi.org/10.1001/jamadermatol.2013.6896

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Rutkowski, P., & Larkin, J. (2024).        Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma        (CheckMate 067): 5-year update. The Lancet Oncology, 23(11), 1430-1442.        https://doi.org/10.1016/S1470-2045(22)00519-0

Wu, S., Han, J., Laden, F., & Qureshi, A. A. (2024). Long-term ultraviolet flux, other potential risk        factors, and skin cancer risk: A cohort study. Cancer Epidemiology, Biomarkers &        Prevention, 23(6), 1080-1089. https://doi.org/10.1158/1055-9965.EPI-13-0821